Pancreatic Involvement in Japanese Patients with Von Hippel-Lindau Disease: Results of a Nationwide Survey

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2013 Apr 2

PMID 23543325

Citations 15

Authors

Hisato Igarashi

Tetsuhide Ito

Isao Nishimori

Kenji Tamura

Ichiro Yamasaki

Masao Tanaka

Taro Shuin

Affiliations

Soon will be listed here.

Abstract

Background: The frequency and prognosis of pancreatic endocrine tumors (PNET)/pancreatic cystic tumors (PCT) in Japanese patients with von Hippel-Lindau disease (VHL) are still open to question.

Methods: We conducted the first nationwide epidemiological study of VHL disease in Japan to elucidate this question. Data on 377 VHL patients (PNET, 53; PCT, 152) were reported, and then their clinical characteristics were analyzed.

Results: PNET was found in 14.1 % and PCT in 40.3 %; 4.5 % had both. The onset of PNET and PCT mostly occurred at 30-39 years of age (median ages, 34 and 33 years, respectively). Metastasis was observed in 7.5 % of PNET patients at diagnosis, and 64.2 % underwent surgery including enucleation, partial and total pancreatectomy, and bypass surgery. Two patients received non-surgical therapies. No PNET-related deaths were observed. In PCT patients, no metastasis was observed at diagnosis, and 9.2 % underwent surgery or drainage. According to the classification system without or with adrenal pheochromocytoma, the VHL patients studied herein were subdivided into 313 (83 %) with VHL type 1 and 64 (17 %) with VHL type 2; 29 (9.3 %) and 24 (37.5 %) patients had PNET with VHL type 1 and 2, suggesting that patients with VHL type 2 were significantly more related to PNET than those with VHL type 1 (P < 0.01).

Conclusions: This study showed no significant difference in the epidemiology of pancreatic involvement between Japanese and non-Japanese VHL patients. Concerning the prognosis, follow-up study is needed.

Citing Articles

New Developments in VHL-Associated Neuroendocrine Neoplasms.

Tsoli M, Panagaki M, Tasouli E, Kolomodi D, Kaltsas G Curr Oncol Rep. 2025; 27(1):59-67.

PMID: 39757325 DOI: 10.1007/s11912-024-01631-5.

Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments.

Kasai Y, Ito T, Masui T, Nagai K, Anazawa T, Uchida Y J Gastroenterol. 2024; 60(1):1-9.

PMID: 39547997 PMC: 11717855. DOI: 10.1007/s00535-024-02166-z.

Von Hippel-Lindau is Associated to Pancreatic Neuroendocrine Tumors: A Comprehensive Review.

Coco D, Leanza S J Kidney Cancer VHL. 2023; 10(2):13-20.

PMID: 37251595 PMC: 10219837. DOI: 10.15586/jkcvhl.v10i2.272.

Large scale genotype- and phenotype-driven machine learning in Von Hippel-Lindau disease.

Chiorean A, Farncombe K, Delong S, Andric V, Ansar S, Chan C Hum Mutat. 2022; 43(9):1268-1285.

PMID: 35475554 PMC: 9356987. DOI: 10.1002/humu.24392.

What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review.

Frey S, Mirallie E, Le Bras M, Regenet N Cancers (Basel). 2021; 13(23).

PMID: 34885063 PMC: 8656750. DOI: 10.3390/cancers13235954.

References

Neumann H, Dinkel E, Brambs H, Wimmer B, FRIEDBURG H, Volk B . Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology. 1991; 101(2):465-71. DOI: 10.1016/0016-5085(91)90026-h. View

Ito T, Sasano H, Tanaka M, Yoshiyuki Osamura R, Sasaki I, Kimura W . Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010; 45(2):234-43. DOI: 10.1007/s00535-009-0194-8. View

Yamasaki I, Nishimori I, Ashida S, Kohsaki T, Onishi S, Shuin T . Clinical characteristics of pancreatic neuroendocrine tumors in Japanese patients with von Hippel-Lindau disease. Pancreas. 2006; 33(4):382-5. DOI: 10.1097/01.mpa.0000240604.26312.e4. View

Hammel P, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas J . Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology. 2000; 119(4):1087-95. DOI: 10.1053/gast.2000.18143. View

Kanno A, Satoh K, Hamada S, Hirota M, Masamune A, Motoi F . Serous cystic neoplasms of the whole pancreas in a patient with von Hippel-Lindau disease. Intern Med. 2011; 50(12):1293-8. DOI: 10.2169/internalmedicine.50.4946. View

Tamura K, Nishimori I, Ito T, Yamasaki I, Igarashi H, Shuin T . Diagnosis and management of pancreatic neuroendocrine tumor in von Hippel-Lindau disease. World J Gastroenterol. 2010; 16(36):4515-8. PMC: 2945481. DOI: 10.3748/wjg.v16.i36.4515. View

Libutti S, Choyke P, Alexander H, Glenn G, Bartlett D, Zbar B . Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery. 2000; 128(6):1022-7;discussion 1027-8. DOI: 10.1067/msy.2000.110239. View

Mukhopadhyay B, Sahdev A, Monson J, Besser G, Reznek R, Chew S . Pancreatic lesions in von Hippel-Lindau disease. Clin Endocrinol (Oxf). 2002; 57(5):603-8. DOI: 10.1046/j.1365-2265.2002.01637.x. View

Binkovitz L, Johnson C, Stephens D . Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. AJR Am J Roentgenol. 1990; 155(3):501-5. DOI: 10.2214/ajr.155.3.1974734. View

10.

Lee K, Lee J, Kim B, Lee J, Kim S, Kim S . Pancreatic involvement in Korean patients with von Hippel-Lindau disease. J Gastroenterol. 2009; 44(5):447-52. DOI: 10.1007/s00535-009-0021-2. View

11.

Delman K, Shapiro S, Jonasch E, Lee J, Curley S, Evans D . Abdominal visceral lesions in von Hippel-Lindau disease: incidence and clinical behavior of pancreatic and adrenal lesions at a single center. World J Surg. 2006; 30(5):665-9. DOI: 10.1007/s00268-005-0359-4. View

12.

Maher E, Neumann H, Richard S . von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011; 19(6):617-23. PMC: 3110036. DOI: 10.1038/ejhg.2010.175. View

13.

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

14.

Charlesworth M, Verbeke C, Falk G, Walsh M, Smith A, Morris-Stiff G . Pancreatic lesions in von Hippel-Lindau disease? A systematic review and meta-synthesis of the literature. J Gastrointest Surg. 2012; 16(7):1422-8. DOI: 10.1007/s11605-012-1847-0. View

15.

Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

16.

Libutti S, Choyke P, Bartlett D, Vargas H, Walther M, Lubensky I . Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery. 1998; 124(6):1153-9. DOI: 10.1067/msy.1998.91823. View

17.

Lonser R, Glenn G, Walther M, Chew E, Libutti S, Linehan W . von Hippel-Lindau disease. Lancet. 2003; 361(9374):2059-67. DOI: 10.1016/S0140-6736(03)13643-4. View

18.

Blansfield J, Choyke L, Morita S, Choyke P, Pingpank J, Alexander H . Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery. 2007; 142(6):814-8. PMC: 6771023. DOI: 10.1016/j.surg.2007.09.012. View

19.

Latif F, Tory K, Gnarra J, Yao M, Duh F, Orcutt M . Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993; 260(5112):1317-20. DOI: 10.1126/science.8493574. View

20.

Maher E, Iselius L, Yates J, Littler M, Benjamin C, Harris R . Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991; 28(7):443-7. PMC: 1016952. DOI: 10.1136/jmg.28.7.443. View